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Abstract
Background: Chronic infection with Pseudomonas aeruginosa is a major cause of morbidity and mortality
in cystic fibrosis (CF) patients, and a more complete understanding of P. aeruginosa within-host genomic
evolution, transmission, and population genomics may provide a basis for improving intervention strategies.
Here, we report the first genomic analysis of P. aeruginosa isolates sampled from Italian CF patients.
Results: By genome sequencing of 26 isolates sampled over 19 years from four patients, we elucidated the
within-host evolution of clonal lineages in each individual patient. Many of the identified mutations were
located in pathoadaptive genes previously associated with host adaptation, and we correlated mutations with
changes in CF-relevant phenotypes such as antibiotic resistance. In addition, the genomic analysis revealed
that three patients shared the same clone. Furthermore, we compared the genomes of the Italian CF isolates
to a panel of genome sequenced strains of P. aeruginosa from other countries. Isolates from two of the Italian lineages
belonged to clonal complexes of P. aeruginosa that have previously been identified in Danish CF patients,
and our genomic comparison showed that clonal isolates from the same country may be more distantly
related than clonal isolates from different countries.
Conclusions: This is the first whole-genome analysis of P. aeruginosa isolated from Italian CF patients, and
together with both phenotypic and clinical information this dataset facilitates a more detailed understanding
of P. aeruginosa within-host genomic evolution, transmission, and population genomics. We conclude that the
evolution of the Italian lineages resembles what has been found in other countries.
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Background
Advances in high-throughput DNA sequencing tech-
niques have made it possible to follow the within-host
genomic evolution of bacterial pathogens by comparing
genomes of longitudinally collected bacterial isolates sam-
pled from human hosts [1]. The genomic information
may be used to understand pathogen population diversity,
host adaptation, and routes and sources of transmission.
Pseudomonas aeruginosa infections in cystic fibrosis
(CF) patients represents an infectious disease scenario in
which within-host genomic evolution of clonal lineages
of infecting bacteria can be followed by making genomic
comparisons of clonal isolates sampled over time [2]. A
number of clinical collections of freeze-stored P. aerugi-
nosa isolates from CF patients have been genome se-
quenced to investigate pathogen microevolution. This
includes investigation of within-host evolution of P. aeru-
ginosa lineages isolated from CF patients from Argentina,
Canada, Denmark, Germany, United Kingdom, and
United States, respectively [3–10]. Nonetheless, to obtain
a more complete basis for understanding P. aeruginosa in-
fections in CF patients and to facilitate comparative stud-
ies to assess the generality of findings, it is necessary to
investigate more clinical collections of P. aeruginosa. In
order to serve as references, such investigations should be
as comprehensive as possible, for example by including
both genomic, phenotypic, and clinical information.
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Here, we report the first genomic analysis of P. aerugi-
nosa isolates sampled from Italian CF patients, aiming to
compare whether within-host evolution of P. aeruginosa
in Italian CF patients resembles what has been found in
other countries.
In total, we sequenced 26 isolates sampled over a
period of 19 years from four different patients. Genomic
comparisons showed that the 26 isolates belonged to six
different clone types (clonal complexes), which we
named IT01-IT06. Each clone type was found to infect a
single patient, except for clone type IT05 that was
shared among three patients.
We conducted both an inter-clonal genomic analysis
to determine the genetic relationship between different
strains, and an intra-clonal genomic analysis to reveal
within-host microevolution of the individual clonal lin-
eages. We correlated the genetic changes with changes
in relevant phenotypes and patient treatment. Finally,
we compared the findings from this study of evolution
of P. aeruginosa in Italian CF patients to the findings
from similar studies encompassing lineages and patient
cohorts from other countries. Altogether, continued
genome sequencing of bacterial pathogens will improve
our understanding of within-host genomic evolution,
transmission, and population genomics.
Results
Collection of P. aeruginosa isolates from Italian CF
patients
In order to investigate the within-host genomic evolu-
tion of P. aeruginosa lineages infecting CF patients, we
performed a retrospective study of a collection of P. aer-
uginosa isolates from four patients attending the Cystic
Fibrosis Center at Anna Meyer’s Children University
Hospital (Florence, Italy). The four patients named E, F,
H and L were all born in the beginning of the 1990s
(1991–1993), and they had their first colonization by
P. aeruginosa within the first three years of life. The
first and subsequent lung isolates of P. aeruginosa
from the four patients were all stored to yield a col-
lection of 35 isolates sampled over a time period of
19 years (1993 to 2012) (Fig. 1).
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Fig. 1 Collection of Pseudomonas aeruginosa isolates. a Information about P. aeruginosa isolates collected from patients E, L, F, and H. AT
genotype refers to the genotype code determined by ArrayTube multimarker microarray. b Longitudinal overview of samples
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The ability of P. aeruginosa to cause infection in CF
patients is not pertained to a single or a few strains (i.e.
clonal complexes or clone types) of P. aeruginosa, and
CF children are anticipated to acquire their first P. aeru-
ginosa infection from environmental strains that are
naïve to the human airways. Accordingly, many different
and unique strains are observed to infect CF patients [9,
11–13]. While the early P. aeruginosa infections may
possibly be eradicated, it is commonly observed that the
same clone type persist in the airways of CF patients,
and a single clone type is typically observed to be dom-
inant [9]. In order to identify such persistent lineages,
we typed the 35 strains using the ArrayTube multimar-
ker microarray targeting 13 single nucleotide polymor-
phisms (SNPs) in the core genome and additional
genetic markers in the accessory genome [13]. Array-
Tube genotyping revealed that all four patients harbored
reoccurring genotypes (Fig. 1). The reoccurrence of
identical bacterial genotypes in the same patient likely
reflect that strains persist in the airways of the patients
[14]. Alternatively, the reoccurrence of identical geno-
types may be due to independent re-colonization from
the same environmental source.
Genome sequencing of isolates to determine genetic
relationships
To further elucidate the possibility that P. aeruginosa
lineages persisted within the airways of the patients, we
genome sequenced 26 of the isolates to investigate their
genomic relationships (Fig. 1). Genome sequencing con-
firmed that isolates of the same genotype were closely
related (i.e. isolates are of the same clonal lineage), and
we name these clonal lineages IT01, IT02, IT03, IT05,
and IT06. Only one isolate of ArrayTube genotype
2C1A was sequenced, and we name this strain IT04.
Isolates of the same lineage differed at most by 84
SNPs (isolates E1 and E36 sampled 17 years apart), and
on average 41 SNPs separated clonal isolates. Most di-
versity was present among isolates of the IT01 lineage
(average genetic distance between IT01 isolates: 57
SNPs), whereas almost no SNP differences were ob-
served between isolates belonging to lineage IT05 (iso-
lates were separated by at most 2 SNPs).
Transmission of the IT05 lineage between patients
Lineages IT01, IT02, IT03, and IT06 were found to in-
fect only a single patient (patients E, H, L, and F, re-
spectively), suggesting that the patients had picked up
the respective lineages from the environment. Contrary,
lineage IT05 was found in both patients F, H, and L, sug-
gesting that the IT05 lineage had spread among the pa-
tients by either direct patient-to-patient transmission or
indirect transmission via a common environmental res-
ervoir. Interestingly, the IT05 lineage is the first clone
type of P. aeruginosa to be isolated from all three pa-
tients in years 1993, 1993, and 1994, respectively. How-
ever, in all cases other clone types of P. aeruginosa
replace the IT05 clone type. We speculate that the IT05
lineage reside in a common environmental source to
which the patients are frequently exposed, enabling the
IT05 lineage to successfully colonize multiple patients,
but that the IT05 lineage in the long run is replaced by
other clone types that are inherently better to thrive in
the patients’ airways.
Phylogeny and mutational signatures
Next, we compared clonally related genomes to recon-
struct the evolutionary history of each of the clonal
lineages (Fig. 2). The mutations in each of the lineages
accumulated in a highly parsimonious fashion (average
parsimonious consistency of 0.99; Table 1), reflecting a
unidirectional and clonal evolution since the most recent
common ancestor. Thus, using a maximum-parsimonious
phylogenetic model, we were able to make accurate infer-
ences about the succession of mutations and the relation-
ship among P. aeruginosa clones.
General conclusions about to what extent natural se-
lection has been the driving force in the fixation of gen-
etic variants, can be inferred from measuring the relative
rates of nonsynonymous (dN) and synonymous (dS)
genetic changes [15]. A dN/dS ratio greater than one im-
plies that there has been an overall positive selection for
mutations; whereas a ratio less than one implies that
there has been a selection for removal of mutations, i.e.
negative selection. However, note that the dN/dS ratio
should be interpreted as an average signal of selection
not giving any information on if both positive and nega-
tive selection has acted at different sites and/or times
during the evolution. We found a significant signature of
negative selection in lineages IT01 (dN/dS = 0.7) and
IT03 (dN/dS = 0.3), whereas the dN/dS ratios in the
other three lineages were neither significantly positive
nor negative (Table 1). Our observed range of dN/dS
from 0.3 to 1.2 is in accordance with previous findings
of within-host microevolution to be affected by both
negative [5, 8] and positive selection [10].
Furthermore, we performed Bayesian analyses of
mutation rates, and we estimated the yearly rate of
SNP mutations in IT01 lineage to be 2.7 SNPs/year
(95 % highest posterior density (HPD; see Methods)
1.0–4.4 SNPs/year), which is equivalent to 4.5 × 10−7
SNPs/year per site. This means that the mutation rate
of the IT01 lineage is almost identical to the within-
host mutation rate (2.6 SNPs/year) estimated for the
DK02 lineage evolving in chronically infected Danish
CF patients [8]. Also, the rate is within the range of
mutation rates estimated in a number of other stud-
ies: Snyder et al. reported a mutation rate of 2.4-3.0
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SNPs/year during a hospital outbreak [16]; Markussen
et al. found the DK01 lineage to accumulate 1.3
SNPs/year in a chronically infected Danish CF patient;
and Cramer et al. estimated the mutation rate of
lineage PA14 to be ~1 SNP/year over the course of
infection of a German CF patient [3]. Mutation rates
of the other lineages (IT02, IT03, IT05, IT06) could
not be estimated since the number and temporal dis-
tribution of isolates were insufficient to obtain proper
estimates of the mutation rates (effective sample sizes
(ESS) of modeled parameters were below 10).
Positive selection for mutations in pathoadaptive genes
Genetic adaptation is hypothesized to play a major role
in the successful establishment of chronic P. aeruginosa
infections of CF patients [3, 8–10, 17–22], and Marvig
et al. recently performed a genome-wide mutational
analysis of 36 different P. aeruginosa lineages to identify
52 candidate ‘pathoadaptive genes’ targeted by muta-
tions to optimize pathogen fitness [9]. We found that
34 of 365 identified intragenic mutations were located
within the 52 candidate pathoadaptive genes, corre-
sponding to an 11-fold enrichment of mutations in
Table 1 Mutations accumulated in Pseudomonas aeruginosa lineages during infection
Lineage IT01 IT02 IT03 IT05 IT06
SNPs 193 38 21 3 48
Missense 104 17 7 1 25
Nonsense 7 1 0 1 2
Silent 53 5 7 1 11
Intergenic 29 15 7 0 10
Intragenic indels 46 23 7 4 43
Intergenic indels 18 6 3 2 13
dN/dS 0.70 1.20 0.33 0.67 0.82
Probability of dN/dS = 1 3.61E-05 8.19E-01 3.95E-04 4.23E-01 1.70E-01
Maximum-parsimonious SNP events 193 39 21 3 48
Parsimony consistency 1.00 0.97 1.00 1.00 1.00
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these particular 52 genes relative to all other genes
(P(X ≥ 34) ~ pois(λ = 3.34) = 7.8 × 10−22, where λ is the
expected number of mutations in 52 genes). This sug-
gests that the mutations in the pathoadaptive genes
have been positively selected in the host airways. In
agreement with this, we found a significant mutational
signature of positive selection of SNPs in pathoadaptive
genes (P = 0.007; dN/dS > 5; 15 nonsynonymous SNPs
and none syonymous SNPs) whereas SNPs in the re-
mainder of genes showed a signature of negative selec-
tion (dN/dS = 0.7). Mutations in pathoadaptive genes
includes nonsynonymous mutations in aceF, algU, bifA,
gyrA, gyrB, lasR, mexA, mexB, mexZ, morA, mucA,
nfxB, pvdS, and retS.
Furthermore, several other of the mutations accumulated
in lineages IT01, IT02, IT03, IT05, and IT06 may as well
confer a selective advantage. For example, the exact C to T
phuR promoter mutation (PAO1 genome position
5289158) found in isolates F23, F40, and F41 has previ-
ously been shown to increase the expression of the Pseudo-
monas heme uptake (phu) system; an adaptive trait shown
to improve the uptake of iron from host hemoglobin [19].
Also, loss-of-function mutations in rpoN have frequently
been found to be typical markers of CF lung infection [10],
and in this study we found an rpoN(11-12insCT) frame-
shift mutation in IT02 strains H24 and H25.
Finally, we identified an A2058G mutation and a
C2611T (Escherichia coli numbering) mutation in the
23S rRNA gene in the IT02 lineage (isolates H24 and
H25) and the IT06 lineage (isolates F23, F40, and F41),
respectively. The exact mutations have previously been
shown to confer macrolide resistance in P. aeruginosa
[20]. Thus, we hypothesize that the mutations have been
selected due the use of azithromycin in clinic (see
Methods section for description of antibiotic therapy),
and in accordance with this the mutations were not ob-
served until after the start of oral azithromycin treat-
ment of the respective patients.
Genetic relationship between IT01-IT06 lineages and
other P. aeruginosa strains
Next, we sought to determine the genetic relationship
between lineages IT01-IT06 and other genome se-
quenced strains of P. aeruginosa. We de novo assembled
the genome of the earliest isolate(s) of each of the six
clonal lineages and aligned the genomes to a panel of 60
genome sequences of other strains of P. aeruginosa. The
panel consisted of eight completed genomes of P. aerugi-
nosa reference strains (PAO1 [23], PA14 [24], LESB58
[25], PA7 [26], DK02 [21], 2192 and C3719 [27],
PACS2), and 53 incomplete draft genomes of strains
DK01-DK53, which we recently genome sequenced in a
study of Danish CF patients [9].
Using the Harvest suite [28], we aligned the panel
of genomes and constructed a phylogenetic tree based
on 188,727 SNPs identified in the core genome of the
aligned strains (Fig. 3). Clustering of genomes based
on core genome SNPs confirmed previous findings
that, except for a few outlier strains (e.g. PA7), strains
group into two major phylogenetic clusters containing
strains PAO1 and PA14, respectively (Fig. 3a) [29, 30].
We observed no evidence that the geographical linked
strains IT01-IT06 grouped more closely in the phylo-
genetic tree. However, we noted that strains IT01-
IT06 all belong to the phylogenetic cluster containing
strain PAO1 (Fig. 3a).
Genetic distances between closely related isolates from
different countries
We found that the IT02 and IT03 lineages were closely
related to isolates of the DK26 and DK06 clone types,
respectively (Fig. 3b), which have been isolated from
Danish CF patients [9]. The close genetic relationship
was also supported by multilocus sequence typing
(MLST) analysis, showing the IT02/DK26 strains to be
of sequence type ST-27 and the IT03/DK06 strains to be
of sequence type ST-17.
To further investigate these two cases, we repeated the
phylogenetic analysis, now only including the relevant iso-
lates (Fig. 4). Note, since both clone types DK06 and
DK26 were found in multiple patients in the study of the
Danish patients, we included the earliest isolate from all
the respective patients in our analysis (DK06 and DK26
isolates were from years 2006–2010 and 2011–2012,
respectively). Interestingly, we found that more diversity
was present between isolates from Denmark relative to
the diversity present between isolates from Italy and
Denmark (Fig. 4). For example, only 47 SNPs separated
the Italian isolate H4 from isolate 294 sampled from a
Danish CF patient (P21F4), whereas Danish isolates of the
same clone type were different by up to 265 SNPs (isolates
294 and 34) (Table 2).
Host adaptation is associated with reduction in metabolic
capacity
Finally, we sought to investigate the phenotypic changes
that occurred during the course of infection. Reductions
in metabolic capacity, for example caused by rpoN muta-
tions, have previously been associated with host adapta-
tion [5, 22], so we used phenotype microarrays (Biolog)
to characterize the metabolic capacity of three strains
from each of the lineages IT01, IT02, and IT06. The
metabolic capacities of isolates of both lineages IT01
and IT02 decreased over time (19 and 10 years, respect-
ively), whereas no change was observed for lineage IT06
over 4 years of infection (Fig. 5).
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Fig. 3 Phylogenetic tree based on core-genome alignment of different Pseudomonas aeruginosa strains. Genomes of the earliest isolate(s) of each
of the lineages IT01-IT06 were aligned against a panel of 60 genome sequences of other strains of P. aeruginosa. a Tree showing the phylogeny
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completed genome sequences) followed by ‘ref’ in parenthesis. Phylogenetic tree was constructed using Harvest [28]
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Mutants with loss-of-function mutations in the CbrAB
two-component system is known to be unable or poor
at utilizing a large range of carbon and nitrogen sources
[31]. Therefore, we speculate that two nonsynonymous
mutations accumulated in cbrAB may explain the loss of
metabolic capacity in isolates H18 and H24 of the IT02
lineage.
In the IT01 lineage, several mutations may explain the
reduced metabolic capacities of isolates E19 and E43
from years 2006 and 2012, respectively, relative to the
ancestral isolate E1 from 1993. Both isolates E19 and
E43 accumulated nonsynonymous mutations in genes
aceF, dgcB, gcdH, glcD, glnD, and vanA belonging to
PseudoCap function classes ‘Amino acid biosynthesis
and metabolism’ and/or ‘Carbon compound catabolism’.
In addition, isolate E43 harbor mutations in genes cysB,
pdxJ, PA4910, sdhA that are involved in biosynthesis of
amino acids, biosynthesis of cofactors, amino acid trans-
port, and central metabolism, respectively. We suggest
that the mentioned mutations may explain the reduction
of metabolic capacity in the IT01 lineage.
Changes in mucoidity, motility, ciprofloxacin
susceptibility, and protease production
Besides reduction in metabolic capacity, the CF lung
infection is associated with the appearance of a num-
ber of other phenotypes of which many are not usually
observed among environmental, wild type isolates of
this species. For example, mucoid colony formation,
reduction in secretion of extracellular proteases, loss
of flagella dependent motility, and antibiotic resistance
0.001
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Fig. 4 Phylogenetic trees based on core-genome alignment of Pseudomonas aeruginosa strains of the IT02/DK26 and IT03/DK06 clonal complexes.
Phylogenetic trees were constructed using Harvest [28]. Name, patient origin, and year of isolation are shown for each isolate in parenthesis
Table 2 Genetic distances (SNPs) between Pseudomonas aeruginosa strains
IT02/DK26 188/P26F5 272/P92F3 382/P99F4 H4
188/P26F5 0 197 108 204
272/P92F3 197 0 41 108
382/P99F4 193 41 0 96
H4 204 108 96 0
IT03/DK06 294/P21F4 295/P21F4 34/P44F5 35/P44F5 398/P77F4 390/P99F4 L6
294/P21F4 0 18 265 259 21 26 47
295/P21F4 18 0 256 258 28 25 58
34/P44F5 265 256 0 23 259 262 277
35/P44F5 259 258 23 0 263 260 277
398/P77F4 21 28 259 263 0 26 53
390/P99F4 26 25 262 260 26 0 64
L6 47 58 277 277 53 64 0
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are characteristics of isolates from chronic CF infec-
tions [32–34].
We phenotypically characterized the 25 isolates of
clone types IT01-IT03 and IT05-06, and in accordance
with previous studies, we found that nearly all isolates
exhibited reduced swimming and swarming motility and
protease secretion relative to the wild type-like reference
strain PAO1 [35] (Fig. 2). The only isolates showing
swimming and/or swarming capabilities better than
PAO1 were L11, F4, and H1. Furthermore, three of the
patients (E, F, and H) harbored mucoid isolates, and the
two latest isolates of the IT02 lineage (H24 and H25)
were resistant to ciprofloxacin.
The relative large numbers of mutations that appear
in each of the clonal lineages make it difficult to associ-
ate specific mutations with phenotypic changes. Nonethe-
less, only mutations GacS(L309Q) and GacA(Y186stop),
respectively, discriminated isolates F4 and H1 from the
other isolates of the IT05 lineage. In agreement with lit-
erature [36, 37], this suggest that the mutations in the
GacAS two-component regulatory system is the cause of
increased motility and decreased extracellular protease ac-
tivity of isolates F4 and H1. Furthermore, we suggest that
a GyrA(T83I) mutation, which has previously been associ-
ated with ciprofloxacin resistance [38], explains ciproflox-
acin resistance observed in isolates H24 and H25. Also,
we suggest that mucoidity of isolates E37 and E42 may be
caused by a nonsense mutation in mucA present in these
two, but no other, isolates of the IT01 lineage.
In the IT02 lineage, a reduction of extracellular protease
activity in isolates H18, H24, and H25 coincides with the
fixation of a missense mutation in lasR encoding a regula-
tor required for the expression of virulence-associated
extracellular proteases LasA and LasB [39, 40]. In the
same isolates, we suggest a loss of swimming motility to
be caused by a missense mutation in fleQ encoding a posi-
tive regulator of flagella biosynthesis genes [41].
Discussion
We have gained insight into P. aeruginosa infections
using a collection of isolates sampled over 19 years from
four Italian CF patients. We sequenced the genomes of
26 of the isolates and correlated identified mutations to
changes in relevant phenotypes and antibiotic treatment
used in the clinic. While there are several other clinical
collections of P. aeruginosa that have been genome se-
quenced [2], this is the first genome analysis of isolates
from Italian CF patients. We therefore anticipate that
our study may serve as a reference for future research
and helps to obtain a more complete basis for under-
standing P. aeruginosa infections in CF patients.
We found the genomic evolution of lineages from
Italian patients to resemble the evolution of P. aerugi-
nosa lineages from other countries. This included
similar observed rates of mutation and evidence for
host-associated selection for mutations in pathoadap-
tive genes. Accordingly, our results support previous
findings of significant mutational signature of positive
selection in relatively few pathoadaptive genes in con-
trast to neutral change in the large remainder of
genes. Inter-study parallelism of mutations in the
same pathoadaptive genes may by part be driven by
similarities in antibiotic treatment regimes. However,
we also found parallelism of mutations in genes that
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are not directly associated to antibiotic resistance (e.g.
aceF, bifA, morA, and retS), and this may reflect simi-
larities in host-dependent selective forces.
Unlike other studies [5, 8, 9, 42–44], we did not iden-
tify hypermutable lineages. Since our study only encom-
passes four patients, the lack of hypermutators may be
accidental, and hypermutators may eventually appear as
these are observed more frequently in late stage infec-
tions [42].
Patients were predominantly infected with strains
unique to the particular patient. One exception was
clone type IT05 which was shared by three patients.
Despite of IT05’s occurrence in multiple patients, the
IT05 clone type resembled a wild type phenotype, and
this may explain why other clone types with typical
host-associated phenotypes replace IT05 in all patients.
As such, the pattern of strain replacement may be due
to initial infections from a strain that reside in a com-
mon environmental source to which the patients are fre-
quently exposed, and that this strain is subsequently
replaced by other more rare, but also more fit, strains.
While other studies have given insight into P. aerugi-
nosa within-host population diversity [5, 7, 45, 46], fur-
ther investigations are needed to make conclusions
about the diversity of P. aeruginosa in our four patients.
However, we conducted an inter-clonal genomic analysis
to determine the genetic relationship between lineages
IT01-IT06 and a panel of 60 genome sequenced strains
of P. aeruginosa from other countries. Hereby, we
showed that lineages IT02 and IT03 were closely related
to lineages DK26 and DK06, respectively, which have
been isolated from Danish CF patients [9]. Since more
diversity was present between isolates from Denmark
relative to the diversity present between isolates from
Italy and Denmark, our findings show that one must be
cautious of using genome analysis to infer the country
origin of lineages.
Conclusions
This is the first whole-genome analysis of P. aeruginosa
isolated from Italian CF patients, and together with both
phenotypic and clinical information this dataset facili-
tates a better understanding of P. aeruginosa within-host
genomic evolution, transmission, and population gen-
omics. This may help the design of future intervention
strategies for the clinical setting.
Methods
Bacterial isolates
The 35 P. aeruginosa isolates used in this study origi-
nates from the bacterial collection available at the Tus-
can Regional Referral Center for Cystic Fibrosis in
Florence, Italy. At this center, P. aeruginosa isolates sam-
pled from CF patients have been stored twice a year
since 1993. All patients enrolled in the study were in
follow-up according to published guidelines [47, 48]. CF
diagnosis was based on clinical features of the disease
and concentration of chloride in sweat >60 mmol/liter
[49]. Patients were regularly examined every 3 months.
Data regarding their weight, height, body mass index
(BMI), forced expiratory volume in one second (FEV1),
microbiological status (including antibodies against P.
aeruginosa) and antibiotic treatments were stored in the
database. Cough swabs or sputum samples were proc-
essed following the national and international guidelines
[50] (https://www.cysticfibrosis.org.uk/media/82034/CD_
Laboratory_Standards_Sep_10.pdf ).
The patients gave written consent to participate and
for publication of their details. The study and use of bac-
terial isolates has been approved by the local ethics com-
mittee at the Department of Paediatric Medicine, Anna
Meyer Children's University Hospital, Florence, Italy
(approval no. 210).
Antibiotic therapy principles in the clinic
Early eradication treatment was started at first detec-
tion of P. aeruginosa by administration of oral cipro-
floxacin in combination with either nebulized colistin
for three weeks or three months or inhaled tobramycin
[48, 51, 52]. When P. aeruginosa reappeared after eradi-
cation therapy, treatment with oral ciprofloxacin and
inhaled antibiotics was restarted.
At development of chronic P. aeruginosa infection
[53], intravenous antibiotic treatment was administered
together with inhaled colistin or inhaled tobramycin. Pa-
tients also received treatments with oral azitromycin
[54]. During follow-up, in the case of mild pulmonary
exacerbation, all patients were treated with oral cipro-
floxacin in combination with inhaled antibiotics. Severe
pulmonary exacerbations were treated with parenteral
antibiotic treatments (ceftazidime or meropenem in
combination with tobramycin once a day) according to
suggested dosage [47].
Patient information
Patient E (cystic fibrosis transmembrane conductance
regulator gene (CFTR) genotype F508del/F508del) had his
first P. aeruginosa colonization at the age of 19 months
and developed chronic infection at the age of three years.
He remained stable without pulmonary exacerbation until
2012. Due to excellent lung function (FEV1 = 115 % of
predicted) he was treated only intermittently with oral cip-
rofloxacin in combination with inhaled antibiotics. Oral
azithromycin was started in 2006.
Patient F (CFTR genotype 711 + 19 A/T /3272-9 A/t)
had her first P. aeruginosa colonization at the age of
33 months and developed chronic infection at the age
of four years. She had a stable FEV1 (60 %) until 2008,
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when she began a progressive clinical deterioration with
FEV1 (20 %) in 2012. She was frequently treated with
high doses of ciprofloxacin with inhaled antibiotics
from 2001 until 2010, with repeated parenteral anti-
biotic cycles with ceftazidime or meropenem in associ-
ation with tobramycin once a day. Oral azithromycin
was started in 2004.
Patient H (CFTR genotype F508del/F508del) had his
first P. aeruginosa colonization at the age of 8 months
and was chronically infected at the age of 1 year. After
chronic P. aeruginosa infection was developed, he was
treated with fluoroquinolones and tobramycin by inhal-
ation. Oral quinolones were used to treat mild pulmon-
ary exacerbations. He underwent parenteral antibiotic
treatment (ceftazidime and tobramycin) twice from 2011
to 2013 for severe pulmonary exacerbations. His lung
function declined from 2006 (FEV1 = 80 %) to 2011
(FEV1 ≤ 40 %). Oral azithromycin was started in 2005. In
addition, tetracyclines, trimethoprim-sulfamethoxazole,
and linezolid were used to treat methicillin-resistant
Staphylococcus aureus.
Patient L (CFTR genotype F508del/N1303K) had her
first P. aeruginosa colonization at the age of 27 months.
She developed chronic infection at the age of 20 years.
However, her clinical conditions were stable and she had
good lung function (FEV1 = 80 %). After chronic P. aeru-
ginosa lung infection developed, she was treated with
antibiotics by inhalation. She used oral quinolones for
mild pulmonary exacerbations together with parenteral
antibiotic treatment (ceftazidime and tobramycin), which
was necessary twice in the period 2011 to 2013. She did
not tolerate treatment with oral macrolides.
ArrayTube genotyping
P. aeruginosa genotypes were determined using an
ArrayTube multimarker microarray targeting 13 SNPs
in the core genome and additional genetic markers in
the accessory genome (Clondiag Chip Technologies,
Germany) [13]. The ArrayTube genotyping assay was
performed according to the protocol provided by the
manufacturer.
Genome sequencing
Genomic DNA was prepared from P. aeruginosa isolates
on a QIAcube system using a DNeasy Blood and Tissue
Kit (Qiagen). Genomes were sequenced by BGI (Shenzhen,
China) to an average coverage depth of at least 75-fold
(range 75- to 139-fold) on an Illumina HiSeq2000 platform
generating 100-nt paired-end reads.
Mutation detection and construction of phylogenetic
trees
Mutations that had accumulated in P. aeruginosa line-
ages IT01-IT03 and IT05-IT06, were identified as
previously described (without any modifications) [9].
Based on the identified SNPs, we computed maximum-
parsimonious phylogenetic trees using PAUP* version
4.0b10 [55]. Consistency indexes were calculated as the
number of mutations divided by the minimum number
of mutational events required to explain phylogenies.
The consistency index will equal one when there is no
homoplasy.
Estimation of mutation rates
Bayesian analysis of evolutionary rate was performed using
BEAST, version 1.7.0 [56], with a lognormal relaxed mo-
lecular clock model and a general time-reversible substitu-
tion model. Mutation rate of the IT01 lineage was
calculated from a chain length of 50 million steps, sam-
pled every 5,000 steps. The first 5 million steps were dis-
carded as a burn-in. The ESS of all parameters were
>1,000 as calculated by Tracer, version 1.5 (available from
http://beast.bio.ed.ac.uk/Tracer), which was also used to
calculate the 95 % HPD confidence intervals of the muta-
tion rate (i.e. an interval within which the modeled param-
eter resides with 95 % probability). Mutation rates of the
other lineages (IT02, IT03, IT05, IT06) could not be esti-
mated since the number and temporal distribution of iso-
lates were insufficient to obtain proper estimates of the
mutation rates (ESS of modeled parameters < 10).
De novo assembly and inter-clonal whole-genome
alignments
We de novo assembled the genome of the earliest iso-
late(s) of each of the six clonal lineages (E1, F23, F24,
H4, L1, L6, L16) and genomes of representatives of
strains DK01-DK53, which we recently genome se-
quenced in a study of Danish CF patients [9].
Sequence reads from each isolate were error corrected
using ALLPATHS-LG’s stand-alone error correction tool
[57] and de novo assembled using the de Bruijn graph-
based assembler Velvet (version 1.2.08) [58]. For each
sample several assemblies were run. This implies that
for each dataset ‘velveth’ command was executed using
k-mer sizes in the range of 35 to 95. Next, the ‘velvetg’
command was run using the parameters: min_con-
tig_lgth = 400, exp_cov = auto, and scaffolding = no.
Based on the number of contigs, the best cumulative
rank for N50, and the length of the largest contig, the
best k-mer size was selected and the exp_cov was noted.
A final assembly was performed using the best k-mer
size for velveth and with velvetg using the parameters:
min_contig_lgth = 400, scaffolding = no, and the exp_cov
that was calculated in the first ensemble of assemblies.
The size range of the de novo assembled genomes of
strains of lineages IT01-06 was 6.3-6.9 Mbp, and each
genome shared 95.8–97.0 % of the content P. aeruginosa
reference strain PAO1.
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De novo assembled genomes and completed genomes
from the public domain [59] were aligned against each
other using the Harvest suite [28] with default parame-
ters using all genomes (option ‘–c’ set to ‘YES’) and with
genome sequence of strain PAO1 as reference.
MLST sequence types were determined using a public
available online tool developed for use on de novo as-
sembled genomes [60]. Sequence types of lineages IT01-
06 were ST-111, ST-27, ST-17, ST-389, ST-1748, and
ST-348, respectively.
Biolog phenotype profiling
Phenotype MicroArray (Biolog, Hayward, CA) experi-
ments were performed in duplicate according to the
manufacturer’s instructions [61, 62]. P. aeruginosa
strains were streaked on LB agar plates and incubated at
37 °C until colonies appeared on the plates (16–30 hours
(h)). Cells were swabbed from the plates and suspended
in IF-0 GN Base (inoculation fluid) at a density corre-
sponding to 42 % transmittance in the Biolog turbidim-
eter. The cell suspensions were diluted 1:6 in IF-0
minimal medium containing Biolog redox dye mixture D
(tetrazolium), and 100-μL aliquots were added to
carbon-source plates (PM1 and PM2A). For the
nitrogen-source plate (PM3B), inoculations were supple-
mented with 30 mM glucose and 2 μM ferric citrate.
The plates were incubated at 37 °C in an OmniLog plate
reader (Biolog) for 72 h, and growth/respiration was
measured kinetically by determining the colorimetric re-
duction of tetrazolium dye. Export of OmniLog data was
performed using OmniLog OL_FM/Kin 1.20.02 software
(Biolog). The average area beneath each kinetic curve
was used for analysis. OD600 was measured after 60 h
of growth at 37 °C, and relative catabolic capacities of
individual substrates were determined as previously de-
scribed [63].
Motility assays
The motility of all isolates was tested on ABT minimal
medium supplemented with 0.5 % Casamino acids and
0.5 % glucose as previously described [64]. Briefly, agar
plates were inoculated with single colonies on the top or
in the middle of the plates to measure swarming or
swimming motility, respectively. Swimming and swarm-
ing were measured on 0.3 % (wt/vol) and 0.6 % (wt/vol)
agar, respectively, with incubation for 24 h at 30 °C. The
motility zones in triplicates were measured relative to
the motility of the reference strain PAO1.
Skim milk protease assay
The production of protease was determined by applying
one colony of the isolate grown on Luria-Bertani (LB)
medium agar plates to skim milk agar plates (LB agar
with 10 % skim milk). The plates were incubated for
24 h at 37 °C, and the clearing zones were measured.
Ciprofloxacin susceptibility testing
Ciprofloxacin susceptibility was tested by the Bauer-Kirby
agar disk diffusion method. Discs (Neo-Sensitabs) were
purchased from Rosco Diagnostica (Taastrup, Denmark).
The diameters of clearing zones were measured in milli-
meters (mm) after 20 h at 37 °C.
Availability of data and materials
Sequence reads from all P. aeruginosa isolates are depos-
ited in the Short Read Archive under accession number
PRJEB8020 [EMBL:PRJEB8020].
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